Intervention

Culmerciclib

ClinicalTrials.gov intervention label

Clinical trials6

Recruiting4

Common conditions9

Lead sponsors shown5

Clinical trials

6 shown

Neoadjuvant Culmerciclib Combined With Endocrine Therapy for Hormone Receptor-Positive， Human Epidermal Growth Factor Receptor 2-Negative Breast CancerNCT07796880 · 2026-09-14

Culmerciclib in HR+/HER2+ Advanced Breast CancerNCT07732491 · 2026-08-01

A Phase II Clinical Study of the Efficacy and Safety of Culmerciclib Rechallenge in HR-positive, HER2-negative Breast Cancer Patients With Resistance to First-line Endocrine Therapy.NCT07666555 · 2026-06-06

Efficacy and Safety of Culmerciclib Plus Aromatase Inhibitors in a Response-Adapted Neoadjuvant Strategy for Highly Proliferative ER-Positive/HER2-Negative Breast CancerNCT07616453 · 2026-05-06

Culmerciclib Combined With Letrozole and Dual HER2 Blockade as Neoadjuvant Therapy for HR+/HER2+ Breast CancerNCT07795424 · 2026-09-01

NOT_YET_RECRUITING

Culmerciclib Plus Anlotinib and Endocrine Therapy for HR-Positive/HER2-Negative Metastatic Breast Cancer With Brain MetastasesNCT07745257 · 2026-08-28

NOT_YET_RECRUITING

Common conditions

Breast Cancer3 Early-Stage Breast Cancer1 HER2 Low Breast Carcinoma1 HER2+ Advanced Breast Cancer1 Hormone Receptor-Positive Breast Cancer1 HR Positive, HER2 Positive Breast Cancer1 HR-positive, HER2-negative Metastatic Breast Cancer With Brain Metastases1 HR+/HER2- Early Breast Cancer1 Metastastic Breast Cancer1

Leading sponsors

Sun Yat-sen University2 Fudan University1 Second Affiliated Hospital, Zhejiang University, School of Medicine1 Shengjing Hospital1 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University1

Trial status mix

RECRUITING4

NOT_YET_RECRUITING2

Phase mix

PHASE26

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.